NCT03274778 2025-11-18
Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells
Oncology Institute of Southern Switzerland
Phase NA Withdrawn
Clinical Trials
5 trialsNCT04354727 2022-07-12
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Ascentage Pharma Group Inc.
Phase 1/2 Withdrawn
NCT02973711 2021-02-16
A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
University of Michigan Rogel Cancer Center
Phase 1/2 Withdrawn
NCT04016116 2020-05-27
Dual PD-1 and JAK2 Inhibition in Hematological Malignancies
NYU Langone Health
Phase 2 Withdrawn
NCT02593929 2017-06-08
Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer
University of Pittsburgh
Phase EARLY_PHASE1 Withdrawn